Diseases / Hidradenitis Suppurativa
Hidradenitis Suppurativa Clinical Trials
DiseaseHidradenitis suppurativa is a chronic inflammatory skin disease characterized by painful, recurrent nodules, abscesses, sinus tracts, and scarring, typically in intertriginous areas such as axillae and groin. Disease course is relapsing and can cause substantial pain, drainage, and psychosocial burden. Pathogenesis involves follicular occlusion with subsequent inflammation and secondary infection.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Hidradenitis Suppurativa
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS NCT07665437 | Phase 3 | Recruiting | Novartis Pharmaceuticals | Started 2026-07 |
| Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients NCT05821478 | Phase 3 | Recruiting | Institut Pasteur | Started 2025-05 |
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib NCT06855498 | Phase 3 | Recruiting | Incyte Corporation | Started 2025-02 |
| The Safety and Efficacy of Roflumilast Foam in HS NCT07263230 | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | Started 2026-09 |
| ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa NCT07783542 | Phase 2 | Recruiting | Oruka Therapeutics, Inc. | Started 2026-08 |
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases NCT07804134 | Phase unknown | Not yet recruiting | Medisch Spectrum Twente | Started 2026-10 |
| Mediterranean Dietary Intervention for HS NCT07800416 | Phase n/a | Not yet recruiting | University of North Carolina, Chapel Hill | Started 2026-09 |
| A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) NCT07766005 | Phase 2 | Not yet recruiting | Spyre Therapeutics, Inc. | Started 2026-09 |
| An Observational Study of Patients With Dermatologic Disease NCT07748169 | Phase unknown | Not yet recruiting | Target PharmaSolutions, Inc. | Started 2026-09 |
| Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa NCT07828860 | Phase 1 | Recruiting | Corvus Pharmaceuticals, Inc. | Started 2026-09 |
Results recently posted
| Trial | Phase | Status | Sponsor | Results posted |
|---|---|---|---|---|
| Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa NCT05322473 | Phase 2 | Completed | MoonLake Immunotherapeutics AG | Results posted 2026-09-09 |
| A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab NCT06241573 | Phase 2/3 | Terminated | Boehringer Ingelheim | Results posted 2026-06-17 |
| Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS). NCT05997277 | Phase 2 | Terminated | Beth Israel Deaconess Medical Center | Results posted 2026-05-29 |
| Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment NCT04414514 | Phase 2 | Terminated | Milton S. Hershey Medical Center | Results posted 2026-04-28 |
| A Bioelectric Dressing for Post De-Roofing Treatment of HS NCT05057429 | Phase n/a | Completed | University of Miami | Results posted 2026-03-06 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 3 | — | — | — | 4 | — | 2 | 1 | — | 10 |
| Phase 1 | 5 | 2 | — | 1 | 8 | — | 1 | — | — | 17 |
| Phase 1/2 | 2 | — | — | — | 3 | — | — | 1 | — | 6 |
| Phase 2 | 13 | 4 | — | 6 | 43 | 9 | 2 | 3 | — | 80 |
| Phase 2/3 | 1 | — | — | — | 1 | 1 | — | — | — | 3 |
| Phase 3 | 3 | — | 1 | 9 | 15 | 2 | — | — | — | 30 |
| Phase 4 | 1 | 2 | — | — | 2 | 1 | 3 | 2 | — | 11 |
| Not applicable | 5 | 4 | — | — | 22 | 6 | 1 | 8 | — | 46 |
| Unknown | 22 | 9 | — | 6 | 24 | 2 | 2 | 9 | 2 | 76 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hidradenitis Suppurativa | 10 | 17 | 6 | 80 | 3 | 30 | 11 | 46 | 76 | 279 |
| Hidradenitis | — | — | 1 | 8 | — | 10 | — | 5 | 3 | 27 |
| Psoriasis | — | 1 | — | 1 | — | 2 | — | 2 | 16 | 22 |
| Dermatitis, Atopic | — | 3 | — | 2 | — | — | — | 1 | 15 | 21 |
| Skin Diseases | — | 1 | — | 9 | — | 6 | — | — | 3 | 19 |
| Alopecia Areata | — | — | — | 1 | — | — | — | 1 | 9 | 11 |
| Arthritis, Rheumatoid | — | 3 | — | — | — | — | — | — | 6 | 9 |
| Vitiligo | — | — | — | 1 | — | — | — | 1 | 7 | 9 |
| Abscess | — | — | — | 3 | — | 1 | — | 1 | 3 | 8 |
| Acne Vulgaris | — | — | — | 1 | — | 3 | — | — | 4 | 8 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Novartis Pharmaceuticals | 20 | 6 |
| 2 | AbbVie | 15 | 3 |
| 3 | Incyte Corporation | 12 | 6 |
| 4 | Henry Ford Health System | 7 | 0 |
| 5 | UCB Biopharma SRL | 6 | 4 |
| 6 | University of Miami | 6 | 0 |
| 7 | Montefiore Medical Center | 5 | 0 |
| 8 | MoonLake Immunotherapeutics AG | 5 | 4 |
| 9 | Boehringer Ingelheim | 4 | 2 |
| 10 | Florida Academic Dermatology Centers | 4 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Adalimumab | 16 |
| 2 | secukinumab | 14 |
| 3 | bimekizumab | 7 |
| 4 | sonelokimab | 5 |
| 5 | brodalumab | 4 |
| 6 | remibrutinib | 4 |
| 7 | Sodium Chloride | 4 |
| 8 | upadacitinib | 4 |
| 9 | apremilast | 3 |
| 10 | Blood Specimen Collection | 3 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06685835 Terminated | Terminated | Lack of Efficacy | 2026-06-08 |
| NCT05066113 Terminated | Terminated | Funding were insufficient to complete | 2026-03-08 |
| NCT05710393 Terminated | Terminated | PI has left the university | 2026-02-27 |
| NCT06555328 Terminated | Terminated | Sponsor Decision | 2026-01-22 |
| NCT06028230 Terminated | Terminated | Sponsor decision. Not related to safety concern. | 2025-11-12 |
| NCT06241573 Terminated | Terminated | 2025-04-11 | |
| NCT05997277 Terminated | Terminated | Funding withdrawn by sponsor due to funding priorities, study cannot continue without funding | 2025-04-10 |
| NCT05905783 Terminated | Terminated | Per our 13Aug24 press release, we announced discontinuation of internal development in this indication. This decision was not due to safety reasons. | 2025-01-27 |
| NCT04414514 Terminated | Terminated | The PI left the Institution and sponsor decided to close the trial. | 2024-02-23 |
| NCT04325607 Terminated | Terminated | Recruitment was affected by the previous COVID pandemic and patient referral pathway was interrupted | 2023-10-01 |
Evidence
- Results reported
- 48.4%59 of 122 completed
- Published
- 11.5%14 of 122 completed
- Primary endpoint met
- 54.4%31 of 57 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 53
- Median duration
- 24.1months
- Countries
- 59
- Study sites
- 4764
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 11
- Phase 1
- 25
- Phase 1/2
- 16
- Phase 2
- 60
- Phase 2/3
- 209
- Phase 3
- 545
- Phase 4
- 30
- Not applicable
- 21
- Unknown
- 154
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 52 |
| 2 | Tampa | United States | 52 |
| 3 | Bochum | Germany | 45 |
| 4 | Miami | United States | 43 |
| 5 | New York | United States | 42 |
| 6 | Los Angeles | United States | 37 |
| 7 | Wroclaw | Poland | 35 |
| 8 | Madrid | Spain | 34 |
| 9 | Berlin | Germany | 33 |
| 10 | Barcelona | Spain | 32 |